ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 78 filers reported holding ALX ONCOLOGY HLDGS INC in Q3 2023. The put-call ratio across all filers is 0.07 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $629,409 | -53.4% | 131,127 | -27.1% | 0.00% | – |
| Q2 2023 | $1,350,050 | +65.3% | 179,767 | -0.5% | 0.00% | – |
| Q1 2023 | $816,525 | -58.7% | 180,647 | +3.0% | 0.00% | – |
| Q4 2022 | $1,977,445 | +28.5% | 175,461 | +9.2% | 0.00% | – |
| Q3 2022 | $1,539,000 | -23.2% | 160,746 | -35.1% | 0.00% | – |
| Q2 2022 | $2,004,000 | -44.7% | 247,743 | +15.5% | 0.00% | -100.0% |
| Q1 2022 | $3,625,000 | +21.2% | 214,486 | +54.2% | 0.00% | 0.0% |
| Q4 2021 | $2,990,000 | -75.2% | 139,138 | -14.6% | 0.00% | -66.7% |
| Q3 2021 | $12,039,000 | +61.5% | 162,996 | +19.6% | 0.00% | +50.0% |
| Q2 2021 | $7,455,000 | -60.1% | 136,333 | -46.2% | 0.00% | -60.0% |
| Q1 2021 | $18,684,000 | +64.7% | 253,385 | +92.5% | 0.01% | +66.7% |
| Q4 2020 | $11,346,000 | +3966.7% | 131,628 | +1683.3% | 0.00% | – |
| Q3 2020 | $279,000 | – | 7,381 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $530,392,000 | 62.60% |
| Logos Global Management LP | 3,156,981 | $172,624,000 | 14.51% |
| Vivo Capital, LLC | 4,220,048 | $230,752,000 | 9.99% |
| Foresite Capital Management V, LLC | 231,200 | $12,642,000 | 4.97% |
| Cormorant Asset Management, LP | 889,454 | $48,635,000 | 1.65% |
| Board of Trustees of The Leland Stanford Junior University | 259,982 | $14,216,000 | 1.33% |
| Redmile Group, LLC | 914,035 | $49,979,000 | 0.74% |
| SPHERA FUNDS MANAGEMENT LTD. | 192,728 | $10,538,000 | 0.71% |
| Financial Advisory Group | 54,041 | $2,955,000 | 0.71% |
| Nan Fung Group Holdings Ltd | 34,950 | $1,911,000 | 0.59% |